Cargando…
Immunological evaluation of a novel HLA-A2 restricted phosphopeptide of tumor associated Antigen, TRAP1, on cancer therapy
The tumor necrosis factor receptor associated protein 1 (TRAP1) is a mitochondria chaperon protein that has been previously implicated as a target for cancer therapy due to its expression level is linked to tumor progression. In this study, an immunodominant phosphopeptide of TRAP1 was identified fr...
Autores principales: | Lin, Min-Han, Shen, Kuan-Yin, Liu, Bing-Sin, Chen, I-Hua, Sher, Yuh-Pyng, Tseng, Guan-Chin, Liu, Shih-Jen, Sung, Wang-Chou |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668235/ https://www.ncbi.nlm.nih.gov/pubmed/31384738 http://dx.doi.org/10.1016/j.jvacx.2019.100017 |
Ejemplares similares
-
A HLA-A2-restricted CTL epitope induces anti-tumor effects against human lung cancer in mouse xenograft model
por: Sher, Yuh-Pyng, et al.
Publicado: (2015) -
A Polypeptide of Tumor-Associated Antigen L6 with Intrinsic Adjuvant Activity Enhances Antitumor Immunity
por: Sher, Yuh-Pyng, et al.
Publicado: (2020) -
The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles
por: Molvi, Zaki, et al.
Publicado: (2023) -
The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles
por: Molvi, Zaki, et al.
Publicado: (2023) -
MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma
por: Engelhard, Victor H, et al.
Publicado: (2020)